WALTHAM, Mass., March 13, 2024 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Stifel 2024 Virtual CNS Days on Wednesday, March 20, 2024 at 8:30 a.m. ET.
A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation.
About Dyne Therapeutics
Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.
Contact:
Dyne Therapeutics
Amy Reilly
areilly@dyne-tx.com
857-341-1203
TORONTO, Feb. 4, 2026 /CNW/ - Canada Health Infoway (Infoway) welcomed today's introduction of Bill S-5, the…
TORONTO, Feb. 4, 2026 /CNW/ - Canada Health Infoway (Infoway) welcomed today's introduction of Bill S-5, the…
CHEYENNE, Wyo., Feb. 4, 2026 /PRNewswire/ -- How can Wyoming employers ensure that new hires…
CHEYENNE, Wyo., Feb. 4, 2026 /PRNewswire/ -- How can Wyoming employers ensure that new hires…
DH100 recognizes the companies shaping the future of healthcare innovation in NY, spotlighting Candid's role…
DH100 recognizes the companies shaping the future of healthcare innovation in NY, spotlighting Candid's role…